IBDEI0UV ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15225,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,15226,0)
 ;;=070.51^^89^903^29
 ;;^UTILITY(U,$J,358.3,15226,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15226,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,15226,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,15226,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,15227,0)
 ;;=070.54^^89^903^30
 ;;^UTILITY(U,$J,358.3,15227,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15227,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,15227,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,15227,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,15228,0)
 ;;=571.41^^89^903^32
 ;;^UTILITY(U,$J,358.3,15228,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15228,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,15228,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,15228,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,15229,0)
 ;;=571.1^^89^903^33
 ;;^UTILITY(U,$J,358.3,15229,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15229,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,15229,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,15229,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,15230,0)
 ;;=070.59^^89^903^34
 ;;^UTILITY(U,$J,358.3,15230,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15230,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,15230,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,15230,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,15231,0)
 ;;=V08.^^89^903^24
 ;;^UTILITY(U,$J,358.3,15231,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15231,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,15231,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,15231,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,15232,0)
 ;;=042.^^89^903^25
 ;;^UTILITY(U,$J,358.3,15232,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15232,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,15232,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,15232,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,15233,0)
 ;;=464.00^^89^903^2
 ;;^UTILITY(U,$J,358.3,15233,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15233,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,15233,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,15233,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,15234,0)
 ;;=790.6^^89^903^1
 ;;^UTILITY(U,$J,358.3,15234,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15234,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,15234,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,15234,2)
 ;;=^87228
 ;;^UTILITY(U,$J,358.3,15235,0)
 ;;=780.60^^89^903^20
 ;;^UTILITY(U,$J,358.3,15235,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15235,1,4,0)
 ;;=4^780.60
 ;;^UTILITY(U,$J,358.3,15235,1,5,0)
 ;;=5^Fever
 ;;^UTILITY(U,$J,358.3,15235,2)
 ;;=^336764
 ;;^UTILITY(U,$J,358.3,15236,0)
 ;;=795.51^^89^903^55
 ;;^UTILITY(U,$J,358.3,15236,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15236,1,4,0)
 ;;=4^795.51
 ;;^UTILITY(U,$J,358.3,15236,1,5,0)
 ;;=5^Pos PPD w/o Active TB
 ;;^UTILITY(U,$J,358.3,15236,2)
 ;;=^340572
 ;;^UTILITY(U,$J,358.3,15237,0)
 ;;=482.9^^89^903^53
 ;;^UTILITY(U,$J,358.3,15237,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15237,1,4,0)
 ;;=4^482.9
 ;;^UTILITY(U,$J,358.3,15237,1,5,0)
 ;;=5^Pneumonia,Bacterial
 ;;^UTILITY(U,$J,358.3,15237,2)
 ;;=^12347
 ;;^UTILITY(U,$J,358.3,15238,0)
 ;;=571.42^^89^903^31
 ;;^UTILITY(U,$J,358.3,15238,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15238,1,4,0)
 ;;=4^571.42
 ;;^UTILITY(U,$J,358.3,15238,1,5,0)
 ;;=5^Hepatitis, Autoimunne
 ;;^UTILITY(U,$J,358.3,15238,2)
 ;;=^336610
 ;;^UTILITY(U,$J,358.3,15239,0)
 ;;=795.52^^89^903^54
 ;;^UTILITY(U,$J,358.3,15239,1,0)
 ;;=^358.31IA^5^2
